Clinical Trials Sponsored by Essenlix Corporation

Total 6496 results

Masimo Corporation

Completed

Validation of Noninvasive Blood Pressure Device

Hypertension | Healthy | Hypotension

United States
Candela Corporation

Active, not recruiting

Functional Usability and Feasibility Testing of the Profound Matrix™ System

Acne Scars - Mixed Atrophic and Hypertrophic | Wrinkle

United States, Israel
Incyte Corporation

Active, not recruiting

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) Malignancies

United States, Netherlands, Spain, United Kingdom, Belgium, Austria
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Incyte Corporation

Active, not recruiting

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Squamous Cell Carcinoma of the Anal Canal

United States, Italy, Spain, United Kingdom, Australia, France, Germany, Sweden, Japan, Norway, Belgium, Denmark, Puerto Rico
Incyte Corporation

Active, not recruiting

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Advanced Solid Tumors

United States, Sweden, Netherlands, Norway, Denmark
Incyte Corporation

Completed

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Ovarian Cancer | Endometrial Cancer | Solid Tumors | Biliary Tract Cancer (BTC) | Colorectal Cancer (CRC) | Gastroesophageal Cancer (GC)

United Kingdom, United States, Belgium
Candela Corporation

Completed

PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles

Benign Pigmented Lesions | Facial Wrinkles

United States
Incyte Corporation

Completed

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Italy, United Kingdom, France, Belgium
PhytoHealth Corporation

Terminated

A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy

Cancer-related Fatigue

Taiwan
PhytoHealth Corporation

Completed

PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy

Cancer-related Fatigue | Neutropenia, Malignant

Taiwan
PhytoHealth Corporation

Completed

PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care

Cancer-related Fatigue

Taiwan
PhytoHealth Corporation

Completed

PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

Neoplasm Metastasis | Neoplasm Recurrence

Taiwan
Pulmonx Corporation

Completed

Post-Market Clinical Evaluation of the Zephyr Valve 5.5-LP EBV

Pulmonary Emphysema

United Kingdom, Switzerland, Germany
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Bronchiolitis Obliterans Syndrome

United States, Belgium, Canada
Candela Corporation

Completed

Clinical Evaluation to Assess the Safety and Efficacy of GentleMax Pro Plus

Onychomycosis | Acne | Wrinkle | Pigmented Lesions | Pseudofolliculitis Barbae | Unwanted Hair | Vascular Lesion

United States
Incyte Corporation

Active, not recruiting

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)

Warm Autoimmune Hemolytic Anemia (wAIHA)

Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
Incyte Corporation

Completed

The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis (SCRATCH-AD)

Atopic Dermatitis

Canada
Incyte Corporation

Completed

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Atopic Dermatitis

United States
Incyte Corporation

Completed

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

B-Cell Malignancies

United States
Glaukos Corporation

Completed

Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution

Glaucoma Open-angle

United States
Glaukos Corporation

Active, not recruiting

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Ocular Hypertension | Glaucoma, Open-Angle

United States
Glaukos Corporation

Completed

Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

Presbyopia

United States
Erchonia Corporation

Terminated

Effect of the Erchonia® HLS™ for the Relief of Tinnitus Symptoms

Tinnitus

United States
Incyte Corporation

Completed

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Polycythemia Vera | Myelofibrosis | Thrombocythemia

Spain, United States, Germany, Austria, Belgium, Italy, Poland
Enimmune Corporation

Enrolling by invitation

A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children

Enterovirus Infections

Taiwan, Vietnam
Incyte Corporation

Completed

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Lymphoma

Japan
Adimmune Corporation

Completed

Dose-finding Study for AdimrSC-2f Vaccine

COVID-19

Indonesia
Masimo Corporation

Completed

Calibration and Validation of the Masimo Temperature Device in Febrile Patients

Fever

United States
Masimo Corporation

Completed

Clinical Performance of Masimo Rad-GT

Healthy

United States
Incyte Corporation

Completed

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Metastatic Melanoma | Unresectable Melanoma | Metastatic Urothelial Cancer | Metastatic Non-small Cell Lung Cancer | Locally Advanced Renal Cell Carcinoma | Locally Advanced Urothelial Cancer | Metastatic Clear-Cell Renal Cell Carcinoma

France, Spain, United States, Italy, Austria, Romania, Poland, Hungary
Masimo Corporation

Completed

Validation of the Masimo INVSENSOR00063 in Febrile and Afebrile Subejcts

Fever

United States
Geron Corporation

Available

Expanded Access for Treatment With Imetelstat

Myelodysplastic Syndromes
Masimo Corporation

Terminated

Validation of RPVi as a Parameter to Predict Fluid Responsiveness

Surgery | Anesthesia

United States
Antengene Corporation

Completed

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma (MARCH)

Relapse/Refractory Multiple Myeloma

China
Seikagaku Corporation

Completed

Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation

Lumbar Vertebra Hernia

United States
Seikagaku Corporation

Completed

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Lumbar Disc Disease | Intervertebral Disc Disease

United States, Germany, Spain, Romania
Seikagaku Corporation

Completed

SI-6603 Versus Placebo in Patients With Lumbar Disc Herniation

Lumbar Vertebra Hernia

Japan
Koning Corporation

Terminated

Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging

Breast Cancer

United States
Incyte Corporation

Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Head and Neck Cancer | Gastric Cancer | Lung Cancer | Metastatic Cancer | Mesothelioma | Bladder Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer)

Italy, Spain, United States, Netherlands
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Acute Graft-versus-host Disease

United States, Spain, France, Italy, United Kingdom, Germany
Incyte Corporation

Approved for marketing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Graft-versus-host Disease (GVHD)
Yuhan Corporation

Completed

A FIH Study of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases

Atopic Healthy Subjects | Adult Subjects With Mild Allergic Diseases

Korea, Republic of
Oxfo Corporation

Completed

Sustainable Preservation of Essential Oxygen Resources: A Phase 4 Crossover Study of the BUFEO System: SAVE O2 (SAVEO2)

Oxygen Deficiency | Oxygen Therapy

Colombia
Genelux Corporation

Completed

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Carcinomatosis

United States
Caerus Corporation

Enrolling by invitation

Study to Evaluate the OrthoCor Active System for Pain Relief

Pain

United States
Mannkind Corporation

Completed

Afrezza With Basal Combination (ABC)

Type 1 Diabetes

United States
Allievex Corporation

Active, not recruiting

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)

Mucopolysaccharidosis Type IIIB

United States, Germany, Spain, Argentina, Australia, Brazil, Colombia, Taiwan, Turkey
Masimo Corporation

Completed

Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00025

Healthy

United States
Yuhan Corporation

Completed

Multi-center, Prospective, Cohort Study to Evaluate the Relationship of Stroke Recurrence and Anti-platelet Resistance in Ischemic Stroke Patients

Ischemic Stroke

Korea, Republic of

Clinical Trials Sponsored by Essenlix Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations